Diffuse large B cell lymphoma (DLBCL) is one of the most common non-Hodgkin lymphoma (NHL).Since the appearance of rituximab,the most common first-line therapy is rituximab in combination with chemotherapy.About 70 percent of patients could achieve complete remission (CR) and be cured finally.But one third of patients could not reach CR after frontline treatment or relapse early,especially the elder patients or high risk ones.In the 56th American Society of Hematology (ASH) annual meeting,a plenty of treatments focusing on these patients brought encouraging results,which makes it possible to further improve the CR rate.The progresses in relapse/refractory,high risk and special site DLBCL will be summarized in this paper based on the reports in the 56th ASH annual meeting.

Diffuse large B-cell lymphoma (DLBCL) is one of the most common non-Hodgkin lymphomaaccounting for 30 %-40 %. The most common first-line therapy for DLBCL is rituximab in combination withchemotherapy. About two thirds of patients treated by the first-line therapy achieve a complete remission (CR)and are cured finally, but nearly one third of patients can not reach CR after frontline treatment appearingrefractory or relapse early, especially for the high risk patients or cases with MYC alterations, the regimenimproving the long-term survival is not much. In the 57th American Society of Hematology (ASH) annualmeeting, a plenty of treatment as focus on these patients brought in encouraging results, which makes itpossible to further improve the CR rate. The progresses on DLBCL of relapse and refractory, high risk andspecial types were summarized in this paper based on the reports in the 57th ASH annual meeting.

Congresses as Topic ; Humans ; Lymphoma, Large B-Cell, Diffuse ; therapy